Device Exits Can Rival Biotech, But Watch Out for the Risks

A look at recent exits challenges the widely held view that device investments have lower return potential than biotech investments. However, a close inspection of the risk/return profile reveals that device investors are taking on more risk than ever.

More from Strategy

More from Business